A federal GranuFlo lawsuit litigation is on track in choosing cases for its upcoming bellwether trials, which will hopefully indicate how future juries will weigh similar arguments against Fresenius Medical Care.

Listed on the agenda of the proceeding’s status conference on May 9th were proposed discovery schedules and trial dates for claims over GranuFlo and NaturaLyte, two dialysis medications allegedly associated with sudden cardiac death, strokes, heart attacks and other cardiovascular problems. These acid concentrates are manufactured by Fresenius Medical Care, and were subject to a Class I recall by the U.S. Food and Drug Administration (FDA) in June 2012 due to the suspected severity of their side effects.

Parties Directed to Submit GranuFlo Lawsuit Selections by September 2014

According to records published on April 15th, at least 1,570 GranuFlo recall lawsuits have now been filed in the federal litigation, which was established in the U.S. District Court, District of Massachusetts in April 2013. Court records indicate that both sides have been directed to submit a list of 10 possible NaturaLyte and GranuFlo lawsuits for trial by September 15, at which time case specific discovery will commence. Following all discovery and depositions into case-specific issues, the GranuFlo lawsuit bellwether trials are slated to begin in either the second half of next year or in early 2016.

All the cases filed in Massachusetts federal court litigation allege similar injuries that occurred after dialysis treatments that used GranuFlo and NaturaLyte, which were distributed in thousands of treatment centers owned by Fresenius prior to the recall, as well as some 125,000 customer clinics throughout the U.S.

Claims against the drug manufacturer similarly allege its failure to not only warn about side effects that may stem from use of their products, but also its possible concealment of dangers they had known about for months prior to the June 2012 recall. Shortly after the FDA action against Fresenius, the federal agency received an internal memo that was sent by the company that previous November, in which physicians operating in its facilities were alerted of 941 patient deaths that occurred after treatments using GranuFlo and NaturaLyte. The company did not warn the general public about side effects linked to the dialysis drugs until March 2012, when an Urgent Product Notification told the U.S. that their high amount of an ingredient the body converts to bicarbonate may result in a condition referred to as metabolic alkalosis.

Filing a GranuFlo Lawsuit

Call an attorney at our Firm to learn more about NaturaLyte and GranuFlo lawsuits, and to find out whether you are eligible to file a claim over the acid concentrates. Call us now at (877) 779-1414.

Published May 12, 2014 by